Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing

Patent 6387403 Issued on May 14, 2002. Estimated Expiration Date:

September 14, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3845770

3916899

Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
Patent #: 3995631
Issued on: 12/07/1976
Inventor: Higuchi , et al.

Osmotic system having laminar arrangement for programming delivery of active agent
Patent #: 4008719
Issued on: 02/22/1977
Inventor: Theeuwes , et al.

Osmotic system for delivering selected beneficial agents having varying degrees of solubility
Patent #: 4111201
Issued on: 09/05/1978
Inventor: Theeuwes

Therapeutic device for osmotically dosing at controlled rate
Patent #: 4160020
Issued on: 07/03/1979
Inventor: Ayer , et al.

Substituted morpholine derivatives and compositions
Patent #: 4229449
Issued on: 10/21/1980
Inventor: Melloni , et al.

Osmotic device with hydrogel driving member
Patent #: 4327725
Issued on: 05/04/1982
Inventor: Cortese , et al.

Osmotic device with wall comprising cellulose ether and permeability enhancer
Patent #: 4519801
Issued on: 05/28/1985
Inventor: Edgren

Delivery system housing a plurality of delivery devices
Patent #: 4578075
Issued on: 03/25/1986
Inventor: Urquhart , et al.

More ...

Inventors

Application

No. 661976 filed on 09/14/2000

US Classes:

424/473, With porous, perforated, apertured, or sieved layer (e.g., dialyzing layer, microporous layer, etc.)424/464, Tablets, lozenges, or pills424/468, Sustained or differential release type424/472Layered unitary dosage forms

Examiners

Primary: Page, Thurman K.
Assistant: Bennett, Rachel M.

Attorney, Agent or Firm

Neller; Robert R.

Foreign Patent References

2167407 GB. 11/13/1984
2 167 407 GB 05/13/1986
WO 99/15176 WO 04/13/1999

International Classes

A61K 009/24
A61K 009/20
A61K 009/22

Abstract

Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Other References

Santus, Giancarlo, Baker, Richard W., "Osmotic Drug Delivery: a review of the patent literature", Journal of Controlled Release, vol. 35 (1995) pp. 1-21, Publisher: Elsevier Science B.V
Berzewski, H., Van Moffaert, M., and Gagiano, C.A., "Efficacy and tolerability of reboxetine compared with imipramine in a double-bind study in patients suffering from major depressive episodes", European Neuro-Psychopharmacology, vol. 7, Suppl. 1 (1997) pp. 537-547, Publisher, Elsevier Science B.